Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

Pexa-Vec (pexastimogene devacirepvec, JX-594) is an oncolytic and immunotherapeutic vaccinia virus designed to destroy cancer cells through viral lysis and induction of granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven tumor-specific immunity. Pexa-Vec has undergone phase 1 and 2 test...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Ther
Prif Awduron: Cripe, Timothy P, Ngo, Minhtran C, Geller, James I, Louis, Chrystal U, Currier, Mark A, Racadio, John M, Towbin, Alexander J, Rooney, Cliona M, Pelusio, Adina, Moon, Anne, Hwang, Tae-Ho, Burke, James M, Bell, John C, Kirn, David H, Breitbach, Caroline J
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2015
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351466/
https://ncbi.nlm.nih.gov/pubmed/25531693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.243
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg